论文部分内容阅读
目的探讨重组人生长激素(rhGH)对青春中、后期特发性矮小症(ISS)患儿的促生长效应。方法于2003-10—2005-03在天津市南开医院就诊的19例青春中、后期ISS患者按骨龄被分为3组,A组骨龄13.0~13.9岁,10例(男7,女3);B组骨龄14.0~14.9岁,6例(男4,女2);C组骨龄15.0~16.0岁,3例(男2,女1)。每晚睡前皮下注射rhGH0.18~0.20IU/kg,共6个月。结果3组ISS患者的身高分别由治疗前(138.4±1.2)cm、(144.2±1.8)cm和(152.8±4.4)cm增至(144.4±1.6)cm、(148.7±1.2)cm和(155.3±6.5)cm。3组患儿于治疗的前3个月促生长效果较明显,后3个月A组的促生长效果明显高于B组、C组,且依次递减,组间生长速度差异有显著性意义(P<0.05);3组患儿用药前、后的体重、骨龄变化差异无显著性意义(P>0.05);所有患者用药前后的甲状腺功能、血糖、血尿常规均正常。结论rhGH治疗对青春中后期特发性矮小症有促生长效应,但应密切随访。
Objective To investigate the effect of recombinant human growth hormone (rhGH) on the growth of children with idiopathic short stature (ISS) in adolescence. Methods A total of 19 middle - and late - stage ISS patients treated in Nankai Hospital of Tianjin from 2003 to 2005 were divided into three groups according to the bone age. Group A was 13.0 to 13.9 years old and 10 (male 7 and female 3). In group B, the bone age was 14.0 to 14.9 years old, 6 cases (male 4 and female 2). The bone age in group C was 15.0 to 16.0 years old and 3 cases (male 2 and female 1). Every night before bedtime injection of rhGH0.18 ~ 0.20IU / kg, a total of 6 months. Results The height of ISS patients in three groups increased from (144.4 ± 1.6) cm to (148.7 ± 1.2) cm and (155.3 ± 6.5) cm. The growth promoting effect of the three groups was obvious in the first three months of treatment, the growth promoting effect of group A was obviously higher than that of group B and C at the third month (P <0.05), and there was a significant difference between the two groups P <0.05). There was no significant difference in body weight and bone age between the three groups before and after treatment (P> 0.05). Thyroid function, blood glucose and hematuria were normal in all patients before and after treatment. Conclusion rhGH treatment can promote the growth of idiopathic short stature in mid-late adolescence, but should be closely followed up.